论文部分内容阅读
目的探讨参芪扶正注射液联合GS方案化疗对晚期胰腺癌气虚证患者的疗效。方法将54例晚期胰腺癌患者随机分为治疗组与对照组各27例,两组均接受GS方案化疗:吉西他滨1000mg/m2,第1天、第8天静脉滴注;替吉奥胶囊根据体表面积确定给药剂量(每日60mg、80mg、100mg),每日2次,连续给药14天后停药7天,21天为1个治疗周期。治疗组同时给予参芪扶正注射液每次250ml,第1-14天静脉滴注,每日1次。记录两组患者生存时间,观察2个周期后气虚证候疗效及毒副反应。结果治疗组患者中位生存时间为10.70个月,对照组为10.01个月,两组比较差异无统计学意义(P>0.05)。治疗组气虚证候改善率为33.3%,对照组为18.5%,治疗组明显高于对照组(P<0.05)。两组毒副反应中中性粒细胞减少和恶心呕吐发生率比较差异均有统计学意义(P<0.05)。结论参芪扶正注射液联合GS方案化疗虽不能提高晚期胰腺癌患者的生存时间,但可减少毒副反应,改善患者气虚症状。
Objective To investigate the effect of Shenqi Fuzheng injection combined with GS regimen chemotherapy in patients with advanced pancreatic Qi-deficiency syndrome. Methods 54 patients with advanced pancreatic cancer were randomly divided into treatment group and control group of 27 cases, both groups received GS regimen chemotherapy: gemcitabine 1000mg / m2, on the first day, on the 8th day intravenous infusion; Surface area to determine the dose (daily 60mg, 80mg, 100mg), 2 times a day, continuous administration of 14 days after the withdrawal of 7 days, 21 days for a treatment cycle. The treatment group also given Shenqi Fuzheng injection 250ml, 1-14 days intravenous infusion, 1 day. Record the survival time of two groups of patients and observe the curative effect and toxicity of Qi deficiency syndrome after 2 cycles. Results The median survival time was 10.70 months in the treatment group and 10.01 months in the control group. There was no significant difference between the two groups (P> 0.05). The improvement rate of Qi deficiency syndrome was 33.3% in the treatment group and 18.5% in the control group, which was significantly higher in the treatment group than in the control group (P <0.05). There was significant difference in the incidence of neutropenia and nausea and vomiting between the two groups (P <0.05). Conclusion Shenqi Fuzheng injection combined with GS regimen does not improve the survival time of patients with advanced pancreatic cancer, but can reduce side effects and improve symptoms of patients with qi deficiency.